ATE207930T1 - Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt - Google Patents
Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibtInfo
- Publication number
- ATE207930T1 ATE207930T1 AT91906615T AT91906615T ATE207930T1 AT E207930 T1 ATE207930 T1 AT E207930T1 AT 91906615 T AT91906615 T AT 91906615T AT 91906615 T AT91906615 T AT 91906615T AT E207930 T1 ATE207930 T1 AT E207930T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- hiv
- binding affinity
- substantially identical
- properties substantially
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 230000027455 binding Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 abstract 1
- 108010015899 Glycopeptides Proteins 0.000 abstract 1
- 102000002068 Glycopeptides Human genes 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 238000001261 affinity purification Methods 0.000 abstract 1
- 230000007717 exclusion Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 abstract 1
- 238000004255 ion exchange chromatography Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000006916 protein interaction Effects 0.000 abstract 1
- 238000004007 reversed phase HPLC Methods 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cookers (AREA)
- Gloves (AREA)
- Table Devices Or Equipment (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49085890A | 1990-03-09 | 1990-03-09 | |
| PCT/US1991/001484 WO1991013906A1 (en) | 1990-03-09 | 1991-03-08 | PURIFIED gp120 COMPOSITION RETAINING NATURAL CONFORMATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE207930T1 true ATE207930T1 (de) | 2001-11-15 |
Family
ID=23949786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91906615T ATE207930T1 (de) | 1990-03-09 | 1991-03-08 | Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0519001B2 (de) |
| JP (2) | JP2624894B2 (de) |
| AT (1) | ATE207930T1 (de) |
| CA (1) | CA2077753C (de) |
| DE (1) | DE69132795T3 (de) |
| IE (1) | IE910779A1 (de) |
| PT (1) | PT96994B (de) |
| WO (1) | WO1991013906A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE207930T1 (de) * | 1990-03-09 | 2001-11-15 | Chiron Corp | Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt |
| EP0527760B1 (de) * | 1990-04-03 | 1995-07-19 | Genentech, Inc. | Methoden und zusammensetzungen zur impfung gegen hiv |
| US7041293B1 (en) | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
| DK0679187T4 (da) † | 1993-01-16 | 2001-09-17 | Manfred Schawaller | Fremgangsmåde til udvinding af native, oligomere, glycosylerede ektodomæner fra virale membranproteiner, og deres anvendelse, især som vaccine mod HIV |
| AU700371B2 (en) * | 1993-06-07 | 1999-01-07 | Genentech Inc. | Hiv envelope polypeptides |
| PT751988E (pt) * | 1994-03-22 | 2000-05-31 | Immune Response Corp Inc | Producao e isolamento altamente eficientes de particulas virais |
| KR100374308B1 (ko) * | 1995-07-27 | 2003-12-18 | 주식회사 엘지생명과학 | 재조합차이니스햄스터오바리세포로부터발현된수두바이러스의지피i당단백질의정제방법 |
| US6585979B1 (en) | 1996-07-08 | 2003-07-01 | Genentech, Inc. | HIV envelope polypeptides and immunogenic composition |
| CA2360347C (en) | 1998-12-31 | 2013-05-07 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| AU2487300A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| JP4776075B2 (ja) | 1998-12-31 | 2011-09-21 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 改変hivenvポリペプチド |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| US7786288B2 (en) * | 2003-10-23 | 2010-08-31 | Karp Nelson M | Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site |
| WO2006011580A1 (ja) * | 2004-07-27 | 2006-02-02 | Genomidea, Inc. | ウイルスエンベロープの精製方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01120284A (ja) * | 1987-11-05 | 1989-05-12 | Shiro Kato | Hiv不完全粒子および該製造方法 |
| ATE207930T1 (de) * | 1990-03-09 | 2001-11-15 | Chiron Corp | Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt |
-
1991
- 1991-03-08 AT AT91906615T patent/ATE207930T1/de not_active IP Right Cessation
- 1991-03-08 CA CA002077753A patent/CA2077753C/en not_active Expired - Lifetime
- 1991-03-08 DE DE69132795T patent/DE69132795T3/de not_active Expired - Lifetime
- 1991-03-08 PT PT96994A patent/PT96994B/pt not_active IP Right Cessation
- 1991-03-08 WO PCT/US1991/001484 patent/WO1991013906A1/en not_active Ceased
- 1991-03-08 IE IE077991A patent/IE910779A1/en not_active IP Right Cessation
- 1991-03-08 JP JP3507168A patent/JP2624894B2/ja not_active Expired - Lifetime
- 1991-03-08 EP EP91906615A patent/EP0519001B2/de not_active Expired - Lifetime
-
1996
- 1996-07-22 JP JP8192595A patent/JPH09227588A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69132795T2 (de) | 2002-06-20 |
| JP2624894B2 (ja) | 1997-06-25 |
| DE69132795D1 (de) | 2001-12-13 |
| JPH05505616A (ja) | 1993-08-19 |
| DE69132795T3 (de) | 2008-07-10 |
| PT96994A (pt) | 1991-10-31 |
| PT96994B (pt) | 1998-07-31 |
| CA2077753A1 (en) | 1991-09-10 |
| JPH09227588A (ja) | 1997-09-02 |
| EP0519001A1 (de) | 1992-12-23 |
| IE910779A1 (en) | 1991-09-11 |
| EP0519001B1 (de) | 2001-10-31 |
| WO1991013906A1 (en) | 1991-09-19 |
| EP0519001B2 (de) | 2007-12-19 |
| CA2077753C (en) | 2000-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE207930T1 (de) | Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt | |
| CA2183888A1 (en) | Antibody purification | |
| DK0731812T3 (da) | Fremgangsmåde til isolering af Poly-beta-1-4-N-Acetylglucosamin | |
| ES2146600T3 (es) | Condroitinasa, procedimiento para su preparacion y composicion farmaceutica. | |
| DK0458841T3 (da) | Fremgangsmåde til anvendelse og fremstilling af peptider | |
| ES2155477T3 (es) | Purificacion cromatografica y procedimiento de separacion de acidos nucleicos. | |
| ES2188665T3 (es) | Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion. | |
| KR960701084A (ko) | 사람 인터루킨-10의 정제방법(Purification of human interleukin-10) | |
| CA1133898A (en) | Purification of interferon | |
| SE8402861L (sv) | Rening av biologiskt material | |
| KR960701098A (ko) | 안티-d 면역글로불린 g 농축액 및 이를 함유하는 약제학적 제제의 제조방법 | |
| DK0646594T3 (da) | Fremgangsmåde til rensning af proteiner | |
| DE69024105D1 (de) | Verfahren zur Herstellung von gereinigten Albuminlösungen | |
| GB2119383A (en) | Homogeneous human immune interferon and process therefor | |
| Piggot et al. | Cyanogen bromide cleavage and partial sequence of the heavy chain of a pathological immunoglobulin G | |
| PT98669A (pt) | Processo para a preparacao da estrutura proteica da toxina de gelonina vegetal | |
| EP0117470B1 (de) | Verfahren zur Herstellung von Interferon (IFN-gamma) des Typs 26K und 21K | |
| CA2356894A1 (en) | Removal of biological contaminants | |
| DE3686961D1 (de) | Polydisperse native pseudomonas-flagella(h)-antigene (fag) und verfahren zu ihrer gewinnung. | |
| DE3650035T2 (de) | THF-Zusammensetzungen. | |
| CA2139931A1 (en) | Purification of Factor IX | |
| Deal et al. | Solubilization, isolation, and immunochemical characterization of the major outer membrane protein from Rhodopseudomonas sphaeroides. | |
| ATE88188T1 (de) | Verfahren zur herstellung von antihaemophilem faktor (faktor viii), der eine hohe reinheit aufweist. | |
| DK0454739T3 (da) | Fremgangsmåde til isolering af oprenset EPI protein fra en opløsning, især en fermenteringsopløsning | |
| ATE155481T1 (de) | Verfahren zur reinigung von streptolysin 0, intaktes streptolysin 0 erhältlich nach diesem verfahren und seine verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| UEP | Publication of translation of european patent specification |
Ref document number: 0519001 Country of ref document: EP |
|
| EELA | Cancelled due to lapse of time |